Review



human cf bronchial epithelial cell line cufi 1  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    ATCC human cf bronchial epithelial cell line cufi 1
    PS/PA liposomes and CKΦ administration does not elicit toxic effects on human CF cells. (A) Cell viability, evaluated by MTT assay, in immortalized human bronchial epithelial cells <t>CuFi-1</t> expressing F508del CFTR control, treated with phosphatidylserine/phosphatidic acid (PS/PA) liposome, CKΦ or combination of PS/PA liposome-CKΦ for 48 h. (B) Cell viability, evaluated by MTT assay, in THP-1 activated macrophage-like cells treated or not with the CFTR inhibitor. Effects of single or combined PS/PA liposome and CKΦ-administration were evaluated after 48 h of treatment. Unpaired Student’s t test: * p < 0.05; ns, not significant. Results are presented as mean ± SEM.
    Human Cf Bronchial Epithelial Cell Line Cufi 1, supplied by ATCC, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human cf bronchial epithelial cell line cufi 1/product/ATCC
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    human cf bronchial epithelial cell line cufi 1 - by Bioz Stars, 2024-10
    93/100 stars

    Images

    1) Product Images from "Evaluation of phages and liposomes as combination therapy to counteract Pseudomonas aeruginosa infection in wild-type and CFTR -null models"

    Article Title: Evaluation of phages and liposomes as combination therapy to counteract Pseudomonas aeruginosa infection in wild-type and CFTR -null models

    Journal: Frontiers in Microbiology

    doi: 10.3389/fmicb.2022.979610

    PS/PA liposomes and CKΦ administration does not elicit toxic effects on human CF cells. (A) Cell viability, evaluated by MTT assay, in immortalized human bronchial epithelial cells CuFi-1 expressing F508del CFTR control, treated with phosphatidylserine/phosphatidic acid (PS/PA) liposome, CKΦ or combination of PS/PA liposome-CKΦ for 48 h. (B) Cell viability, evaluated by MTT assay, in THP-1 activated macrophage-like cells treated or not with the CFTR inhibitor. Effects of single or combined PS/PA liposome and CKΦ-administration were evaluated after 48 h of treatment. Unpaired Student’s t test: * p < 0.05; ns, not significant. Results are presented as mean ± SEM.
    Figure Legend Snippet: PS/PA liposomes and CKΦ administration does not elicit toxic effects on human CF cells. (A) Cell viability, evaluated by MTT assay, in immortalized human bronchial epithelial cells CuFi-1 expressing F508del CFTR control, treated with phosphatidylserine/phosphatidic acid (PS/PA) liposome, CKΦ or combination of PS/PA liposome-CKΦ for 48 h. (B) Cell viability, evaluated by MTT assay, in THP-1 activated macrophage-like cells treated or not with the CFTR inhibitor. Effects of single or combined PS/PA liposome and CKΦ-administration were evaluated after 48 h of treatment. Unpaired Student’s t test: * p < 0.05; ns, not significant. Results are presented as mean ± SEM.

    Techniques Used: MTT Assay, Expressing



    Similar Products

    human cf bronchial epithelial cell line cufi 1  (ATCC)
    93
    ATCC human cf bronchial epithelial cell line cufi 1
    PS/PA liposomes and CKΦ administration does not elicit toxic effects on human CF cells. (A) Cell viability, evaluated by MTT assay, in immortalized human bronchial epithelial cells <t>CuFi-1</t> expressing F508del CFTR control, treated with phosphatidylserine/phosphatidic acid (PS/PA) liposome, CKΦ or combination of PS/PA liposome-CKΦ for 48 h. (B) Cell viability, evaluated by MTT assay, in THP-1 activated macrophage-like cells treated or not with the CFTR inhibitor. Effects of single or combined PS/PA liposome and CKΦ-administration were evaluated after 48 h of treatment. Unpaired Student’s t test: * p < 0.05; ns, not significant. Results are presented as mean ± SEM.
    Human Cf Bronchial Epithelial Cell Line Cufi 1, supplied by ATCC, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human cf bronchial epithelial cell line cufi 1/product/ATCC
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    human cf bronchial epithelial cell line cufi 1 - by Bioz Stars, 2024-10
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    PS/PA liposomes and CKΦ administration does not elicit toxic effects on human CF cells. (A) Cell viability, evaluated by MTT assay, in immortalized human bronchial epithelial cells CuFi-1 expressing F508del CFTR control, treated with phosphatidylserine/phosphatidic acid (PS/PA) liposome, CKΦ or combination of PS/PA liposome-CKΦ for 48 h. (B) Cell viability, evaluated by MTT assay, in THP-1 activated macrophage-like cells treated or not with the CFTR inhibitor. Effects of single or combined PS/PA liposome and CKΦ-administration were evaluated after 48 h of treatment. Unpaired Student’s t test: * p < 0.05; ns, not significant. Results are presented as mean ± SEM.

    Journal: Frontiers in Microbiology

    Article Title: Evaluation of phages and liposomes as combination therapy to counteract Pseudomonas aeruginosa infection in wild-type and CFTR -null models

    doi: 10.3389/fmicb.2022.979610

    Figure Lengend Snippet: PS/PA liposomes and CKΦ administration does not elicit toxic effects on human CF cells. (A) Cell viability, evaluated by MTT assay, in immortalized human bronchial epithelial cells CuFi-1 expressing F508del CFTR control, treated with phosphatidylserine/phosphatidic acid (PS/PA) liposome, CKΦ or combination of PS/PA liposome-CKΦ for 48 h. (B) Cell viability, evaluated by MTT assay, in THP-1 activated macrophage-like cells treated or not with the CFTR inhibitor. Effects of single or combined PS/PA liposome and CKΦ-administration were evaluated after 48 h of treatment. Unpaired Student’s t test: * p < 0.05; ns, not significant. Results are presented as mean ± SEM.

    Article Snippet: The human CF bronchial epithelial cell line CuFi-1 (ATCC CRL-4013™) were grown as monolayer cultures as previously described ( ).

    Techniques: MTT Assay, Expressing